IL298991A - Low-dose pharmaceutical preparations of GHRH analogs and their uses - Google Patents

Low-dose pharmaceutical preparations of GHRH analogs and their uses

Info

Publication number
IL298991A
IL298991A IL298991A IL29899122A IL298991A IL 298991 A IL298991 A IL 298991A IL 298991 A IL298991 A IL 298991A IL 29899122 A IL29899122 A IL 29899122A IL 298991 A IL298991 A IL 298991A
Authority
IL
Israel
Prior art keywords
low
pharmaceutical compositions
dose pharmaceutical
ghrh analogs
ghrh
Prior art date
Application number
IL298991A
Other languages
English (en)
Hebrew (he)
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Publication of IL298991A publication Critical patent/IL298991A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL298991A 2020-07-05 2021-06-30 Low-dose pharmaceutical preparations of GHRH analogs and their uses IL298991A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063048167P 2020-07-05 2020-07-05
PCT/CA2021/050904 WO2022006657A1 (en) 2020-07-05 2021-06-30 Low-dose pharmaceutical compositions of ghrh analogs and uses thereof

Publications (1)

Publication Number Publication Date
IL298991A true IL298991A (en) 2023-02-01

Family

ID=79553399

Family Applications (1)

Application Number Title Priority Date Filing Date
IL298991A IL298991A (en) 2020-07-05 2021-06-30 Low-dose pharmaceutical preparations of GHRH analogs and their uses

Country Status (9)

Country Link
US (1) US20230270865A1 (cg-RX-API-DMAC7.html)
EP (1) EP4175661A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023533498A (cg-RX-API-DMAC7.html)
KR (1) KR20230035600A (cg-RX-API-DMAC7.html)
CN (1) CN115884783A (cg-RX-API-DMAC7.html)
AU (1) AU2021306736A1 (cg-RX-API-DMAC7.html)
CA (1) CA3183299A1 (cg-RX-API-DMAC7.html)
IL (1) IL298991A (cg-RX-API-DMAC7.html)
WO (1) WO2022006657A1 (cg-RX-API-DMAC7.html)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003229222B2 (en) * 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
MX2009010675A (es) * 2007-04-04 2009-10-23 Theratechnologies Inc Formulaciones farmaceuticas de moleculas de la hormona liberadora de la hormona delcrecimiento humana.
EP2421548A4 (en) * 2009-04-20 2012-09-26 Theratechnologies Inc USE OF (HEXENOYL TRANS-3) HGRF (1-44) NH2 AND SIMVASTATIN IN COMBINED TREATMENT
BR112013027150A2 (pt) * 2011-04-21 2017-06-06 Theratechnologies Inc thera
US8871713B2 (en) * 2013-03-01 2014-10-28 Theratechnologies Inc. Formulations of growth hormone releasing factor (GRF) molecules with improved stability
US20170037105A1 (en) * 2015-08-03 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20200297817A1 (en) * 2019-03-22 2020-09-24 Theratechnologies Inc. Pharmaceutical compositions of ghrh analogs and uses thereof
CA3037757A1 (en) * 2019-03-22 2020-09-22 Theratechnologies Inc. Pharmaceutical compositions of ghrh analogs and uses thereof
WO2020205498A1 (en) * 2019-03-29 2020-10-08 The General Hospital Corporation Ghrh or analogues thereof for use in treatment of hepatic disease

Also Published As

Publication number Publication date
AU2021306736A1 (en) 2023-01-19
KR20230035600A (ko) 2023-03-14
JP2023533498A (ja) 2023-08-03
EP4175661A1 (en) 2023-05-10
US20230270865A1 (en) 2023-08-31
CN115884783A (zh) 2023-03-31
EP4175661A4 (en) 2024-08-07
WO2022006657A1 (en) 2022-01-13
CA3183299A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
IL310530A (en) Stabilized compositions of radionuclides and their uses
IL286726A (en) Medical preparations and combinations containing androgen receptor inhibitors and their uses
IL292439A (en) Pharmaceutical preparations of albumin and rapamycin
GB2611642B (en) Pharmaceutical and cosmetic compositions comprising secretomes
PT4153133T (pt) Composições farmacêuticas injetáveis e utilizações das mesmas
IL316049A (en) Musuntuzumab pharmaceutical preparations and methods of use
RS67114B1 (sr) Oralno raspadajuće farmaceutske kompozicije apiksabana
IL311284A (en) Chloride-converted tetralin compounds and pharmaceutical preparations
IL315617A (en) Preparations with improved bioavailability of drugs and their uses
IL327150A (en) Pharmaceutical preparations
GB202406893D0 (en) Therapeutic and preventive compositions
HK40091688A (en) Low-dose pharmaceutical compositions of ghrh analogs and uses thereof
HUE066812T2 (hu) Az utidelone szilárd, orális készítménye
IL306032A (en) Compositions of SOLABEGRON in micronization and methods of use
DK4126898T3 (en) Budesonide 21-phosphate salts and pharmaceutical compositions containing the same
GB2626266B (en) Oral pharmaceutical compositions of progesterone and estradiol
IL326970A (en) Pharmaceutical preparations containing nifocalimab
IL314046A (en) RIBOCICLIB medicinal preparations
EP4370117A4 (en) PHARMACEUTICAL COMPOSITIONS OF OZANIMOD
GB202003316D0 (en) Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof
IL327411A (en) Pharmaceutical preparations containing maralicife and their uses
SI4531816T1 (sl) Farmacevtske formulacije biktegravirja in lenakapavirja
GB202314361D0 (en) Vaccine compositions and uses thereof
GB202209022D0 (en) Pharmaceutical compositions and formulations for the treatment of retinoblastoma
HUE064547T2 (hu) Gyengén ionizálható vagy nem ionizálható gyógyszerészeti hatóanyagok ön-emulgeáló kompozíciói